SALT LAKE CITY — In this video, Jay Chhablani, MD, discusses findings from the LIGHTSITE 3B study presented at the ARVO meeting on the long-term use of photobiomodulation in dry age-related macular degeneration.
The open-label extension study included 63 eyes of 36 patients. The Valeda light delivery system (LumiThera) was used every 4 months for 13 months. The photobiomodulation group showed greater improvement in vision than the sham group, with treatment-naive cases improving by more than five letters, according to Chhablani, professor of ophthalmology at University of Pittsburgh